Last updated: July 16, 2026
IMPACTX LABORATORIES LLC v. ASCENT PHARMACEUTICALS INC. 1:24-cv-05299 Litigation Summary, Claims, and Exclusivity Risk
What is the case caption and docket number for Impax Laboratories v. Ascent Pharmaceuticals?
Case: IMPAX LABORATORIES, LLC v. ASCENT PHARMACEUTICALS INC.
Docket: 1:24-cv-05299
Year filed: 2024
Parties (as captioned):
- Plaintiff: Impax Laboratories, LLC
- Defendant: Ascent Pharmaceuticals Inc.
What court is 1:24-cv-05299 filed in, and who are the litigants?
The supplied docket identifier is insufficient to determine the filing court, venue, judge, or jurisdictional specifics with certainty.
What patents are at issue in 1:24-cv-05299?
The provided case identifier alone does not include the Orange Book listing(s), asserted patent numbers, or claim(s)-in-suit. A complete litigation summary requires the complaint, infringement contentions, or docket docket-sheet entries.
What is the asserted drug and FDA reference product (Orange Book context) for this dispute?
The docket number alone does not identify:
- the ANDA/BLA product name
- the reference listed drug (RLD)
- the submitted paragraph (IV, I, or other)
- the FDA approval pathway
- the drug strength/dosage form implicated
What claims are alleged in the complaint (infringement theories and remedies sought)?
The docket identifier alone does not include:
- infringement theory (direct, induced, contributory)
- asserted methodology vs composition claims
- declaratory relief requests
- requested injunction scope (PI or TU status)
- damages vs equitable relief posture
How strong is Impax’s litigation position in this case?
A strength analysis is only possible once the asserted patent estate and procedural posture are known (e.g., claim construction status, stipulations, PRF/ANDA amendments, settlement timelines).
With only 1:24-cv-05299 and no pleaded patents or schedule entries, the litigation strength cannot be characterized from the provided information.
When does exclusivity expire for the product tied to 1:24-cv-05299?
Exclusivity and patent term timing depend on the specific RLD and Orange Book codes (e.g., NCE, orphan, pediatric exclusivity, method-of-use vs formulation vs polymorph).
No RLD, drug, or patent numbers are provided in the prompt, so exclusivity timing cannot be stated.
Is this litigation a Paragraph IV challenge, and what does that imply for generic entry?
Whether this is a Paragraph IV Abbreviated New Drug Application (ANDA) challenge requires the complaint allegations or ANDA submission details.
No paragraph basis is provided.
What settlement or agreement terms are typical for this type of Hatch-Waxman case?
Specific settlement terms depend on:
- whether a final judgment has issued
- whether a consent judgment has been entered
- whether a “30-month stay” is in play
- the design-around or carve-out terms
No settlement details are provided.
What is the case procedural status for 1:24-cv-05299?
A procedural posture summary requires docket events such as:
- complaint filing date
- service/answer date
- Rule 16 scheduling order
- claim construction briefing
- Markman hearing date
- expert report deadlines
- motions to dismiss / transfer
- dispositive motion decisions
None of these are included.
Which patents typically get litigated in Impax vs generic defendants, and how does that map to likely risk areas?
Even without the asserted patents, the categories in Hatch-Waxman disputes usually include one or more of:
- formulation patents (controlled-release coatings, excipient systems, dissolution profiles)
- method-of-use patents (dose timing, patient population, dosing regimen)
- polymorph/crystal form patents
- manufacturing/process patents
- combination claims (if applicable)
However, mapping categories to this specific case requires the pleaded patent list.
Key Tables
1) Case identity and basic docket data
| Field |
Value |
| Case caption |
IMPAX LABORATORIES, LLC v. ASCENT PHARMACEUTICALS INC. |
| Docket number |
1:24-cv-05299 |
| Plaintiff |
Impax Laboratories, LLC |
| Defendant |
Ascent Pharmaceuticals Inc. |
| Filing year |
2024 |
2) Litigation elements needed for full analysis
| Element |
Needed input |
| Asserted patent numbers |
Complaint or infringement contentions |
| Patent claim scope |
Claim construction briefing/orders |
| ANDA/RLD and product |
Complaint and Orange Book listing |
| Paragraph basis |
Complaint allegations (IV/I/other) |
| Status |
Docket events and orders |
| Settlement / consent judgment |
Court docket entries and filings |
Key Takeaways
- The prompt provides only the case caption and docket number (1:24-cv-05299).
- No asserted patents, RLD/ANDA product, paragraph basis, court, or procedural events are included, so a complete litigation summary and analysis cannot be produced from the provided information.
FAQs
- What is the difference between a Hatch-Waxman Paragraph IV ANDA challenge and a generic litigation based on non-Orange Book patents?
- How do claim construction outcomes typically affect settlement leverage in ANDA patent cases?
- What information in a district court docket most strongly predicts an injunction outcome?
- How do formulation patents (controlled-release coatings/excipients) change generic design-around strategies?
- When do 30-month stays typically lift relative to patent litigation milestones?
References
No sources were provided in the prompt, and no external citations can be supported from the limited docket identifier alone.
